1. Scrip
  2. >>Focus On Asia
  3. >>Japan

MSD To Launch Rotavirus Vaccine Rotateq In Japan

Merck & Co. subsidiary Merck Sharp & Dohme Ltd. announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20.

Merck & Co. subsidiaryMerck Sharp & Dohme Ltd.announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20. Most children who suffer from the rotavirus are infected by the illness by the age of 5, experiencing diarrhea, vomiting, and fever, but complications can also lead to dehydration, cramps, and even encephalitis. Currently, only symptomatic treatment exists for the illness, but MSD aims to spread prevention through vaccination. Rotavirus has many serotypes, but 90% of cases are caused by G1P(8), G2P(4), G3P(8), G4P(8), or (G9P(8). The vaccine targets these serotypes with a 100% efficacy against severe rotavirus gastroenteritis. (Click Here For More – Japanese Language)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

 
• By Dexter Jie Yan

Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.